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Background: Massively parallel sequencing (MPS) has revolutionised biomedical research and offers enormous
capacity for clinical application. We previously reported Hi-Plex, a streamlined highly-multiplexed PCR-MPS
approach, allowing a given library to be sequenced with both the Ion Torrent and TruSeq chemistries. Comparable
sequencing efficiency was achieved using material derived from lymphoblastoid cell lines and formalin-fixed
paraffin-embedded tumour.
Methods: Here, we report high-throughput application of Hi-Plex by performing blinded mutation screening of
the coding regions of the breast cancer susceptibility gene PALB2 on a set of 95 blood-derived DNA samples that
had previously been screened using Sanger sequencing and high-resolution melting curve analysis (n = 90), or
genotyped by Taqman probe-based assays (n = 5). Hi-Plex libraries were prepared simultaneously using relatively
inexpensive, readily available reagents in a simple half-day protocol followed by MPS on a single MiSeq run.
Results: We observed that 99.93% of amplicons were represented at ≥10X coverage. All 56 previously identified
variant calls were detected and no false positive calls were assigned. Four additional variant calls were made and
confirmed upon re-analysis of previous data or subsequent Sanger sequencing.
Conclusions: These results support Hi-Plex as a powerful approach for rapid, cost-effective and accurate
high-throughput mutation screening. They further demonstrate that Hi-Plex methods are suitable for and can
meet the demands of high-throughput genetic testing in research and clinical settings.
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Recently, there has been considerable discussion regarding
how massively parallel sequencing (MPS) can optimally
be applied in the context of clinical genetics services.
Whole-genome MPS remains prohibitive in terms of
cost, throughput, data handling and bioinformatic analysis
complexity, as well as challenging clinical interpretation
and raising many issues around the ethics of reporting
results. Targeted MPS can address these issues by* Correspondence: djp@unimelb.edu.au
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article, unless otherwise stated.efficiently restricting clinical testing to sets of genes or
genomic regions with known diagnostic value, while
providing marked time- and cost-related advantages
over traditional Sanger sequencing-based strategies.
We previously developed and reported Hi-Plex, a
streamlined highly-multiplexed PCR approach for MPS
library preparation, using DNA derived from both
lymphoblastoid cell line and formalin-fixed, paraffin-
embedded tumour tissue [1]. Our Hi-Plex library-building
method integrates simple, automated primer design soft-
ware that enables control of amplicon size. Importantly,
this feature allows complete overlap of read pairs following
paired-end sequencing to facilitate stringent downstreamd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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that Hi-Plex using hybrid adapter primers (containing
5′-TruSeq compatible and 3′-Ion Torrent compatible
sequences) can produce libraries suitable for both the Ion
Torrent (PGM and Proton instruments, Life Technologies,
Carlsbad, CA, USA) and TruSeq (MiSeq and HiSeq
instruments, Illumina, San Diego, CA, USA) systems,
which currently represent the two most commonly
used MPS chemistries [2].
To assess the effectiveness of Hi-Plex in a high-
throughput context, we used the MiSeq platform to
perform mutation screening of 95 specimens, including
three duplicated specimens, screened previously for
genetic variants in the breast cancer susceptibility
gene PALB2 (GenBank reference sequence NM_024675;




Our sample set consisted of 95 blood-derived DNAs
derived from women affected by breast cancer that had
been screened previously for mutations in the coding and
flanking intronic regions of PALB2 (n = 90) or genotyped
for known PALB2 pathogenic mutations (n = 5). All partic-
ipants provided written informed consent for participation
in the study. This study was approved by The University
of Melbourne Human Research Ethics Committee.
Biological samples were provided by the Australian
Breast Cancer Family Registry (ABCFR, 91 specimens,
of which three were duplicated specimens) and the
Kathleen Cuningham Foundation Consortium for research
into Familial Breast cancer (kConFab, Melbourne,
Australia, four specimens). DNAs from both resources
were extracted using QIAamp DNA Blood Kit (Qiagen,
Hilden, Germany). Quant-iT™ PicoGreenW dsDNA Assay
Kit (Life Technologies) was used for quantification.
Previous screens were done by Sanger sequencing and
high-resolution melting curve analysis (HRM) for 85
specimens, including the duplicates, whereas HRM only
was applied to five specimens. We included five speci-
mens carrying pathogenic non-sense mutations identi-
fied previously by Taqman probe-based assays: PALB2:
c.196C>T (n = 1) and PALB2:c.3113G>A (n = 4). Sanger
sequencing was performed as previously described in [3]
(unpublished data). HRM and Taqman probe-based as-
says are described in [4] and results of variant detection
are reported in [4,5].
Mutation screening using Hi-Plex
This Hi-Plex assay was designed to target the PALB2
and XRCC2 genes. However, genotyping aspects of this
study focus on PALB2 only, as we did not have a similar
test set with genotype data for XRCC2.Sixty primer pairs targeting the protein coding and
some flanking intronic and untranslated regions of
PALB2 and XRCC2 are described in [1] and Additional
file 1. Dual-indexed hybrid adapter primer sets are
described in Additional file 2. All oligonucleotides were
obtained from Integrated DNA Technologies (Coralville,
IA, USA).
96 individual PCR reactions (95 specimen DNAs and
one no-template control) were performed in a standard
skirted PCR plate, in a final volume of 50 μl, with1X
Phusion® HF PCR buffer (ThermoScientific, Waltham,
MA, USA), 2 units of Phusion Hot Start II High-Fidelity
DNA Polymerase (ThermoScientific), 400 μM dNTPs
(Bioline, London, UK), approximately 0.5 μM gene-specific
primer pool (individual gene-specific primer concentra-
tions vary and are described in [2]), 2.5 mM MgCl2
(ThermoScientific) and 25 ng input genomic DNA. The
following steps were then applied to conduct PCR: 98°C
for 1 min, 6 cycles of [98°C for 30 sec, 50°C for 1 min,
55°C for 1 min, 60°C for 1 min, 65°C for 1 min, 70°C
for 1 min], addition of 2 μM each dual-indexed hybrid
N50#_TSIT_A and N70#_TSIT_P adapter primers, then a
further 19 cycles of [98°C for 30 sec, 50°C for 1 min, 55°C
for 1 min, 60°C for 1 min, 65°C for 1 min, 70°C for 1 min],
followed by incubation at 60°C for 20 min. Five μl of each
reaction were pooled before subjecting the resulting
barcoded library (including the 96 sub-libraries) to
electrophoresis on a 2% HR-agarose gel (Life Technolo-
gies). Size selection, gel extraction and purification were
performed as described previously [1].
The library was then sequenced on a MiSeq instrument,
using the MiSeq Reagent kit v2 300 cycles (Illumina). Prior
to performing the run, 3.4 μL of 100 μM sequencing
primers were added to the respective read1, read2 and i7
primer reservoirs in the reagent cartridge. Sequencing
primers were obtained from Integrated DNATechnologies
(sequences are provided in Additional file 2).
Sequencing data were mapped to the entire human
genome (hg19) using bowtie2-2.1.0 [6] applying default
parameters except for –trim5 20 –trim3 20. Bedtools
v2.16.1 [7] was used to compute on-target coverage. We
used ROVER variant caller, a software tool developed
in-house and made available at https://github.com/
bjpop/rover to perform automated variant calling. To
be called in this application, genetic variants had to
appear in i) both members of read-pairs; ii) at least 2
read-pairs; and iii) ≥ 15% of read-pairs. Homozygous
variants were called when the minor allele was present
in ≥85% of read-pairs. The tool also reports the number
of read pairs covering each targeted amplicon. Sequencing
statistics reported in this paper (on-target and coverage
calculations) include both XRCC2 and PALB2, as they
represent all the targeted regions. To assess the efficiency
of the 60-plex assay across all 95 specimens, depth of
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in total.
When validation was required for a genetic variant
identified by Hi-Plex but not reported in previous
screens, Sanger sequencing was performed using BigDye
Terminator v3.1 (Life Technologies), according to the
manufacturer’s instructions.
Results and discussion
In our set of 95 samples, of reads mapping to the hg19
human genome build an average of 96.62% were on
target. Across samples, the on-target rate ranged from
93.01% to 98.26% and the total number of reads that
mapped on-target ranged from 7,933 to 171,466. When
considering only correctly paired, on-target reads, we
observed that 99.93% (5,696/5,700) of amplicons were
represented at ≥10× coverage, across samples. Add-
itionally, we found that 88.3% (5037/5700), 96.02%
(5472/5700), 98.54% (5617/5700) and 99.30% (5660/
5700) of amplicons were represented within 5-fold,
10-fold, 20-fold and 30-fold of the median coverage.
Additional file 3 illustrates the coverage distribution
across a sample of BAM files.Table 1 PALB2 variants identified in previous screens (Sanger
(Taqman probe-based), and detected via Hi-Plex
Variant type Nucleotide changea Protein change rs numb
Non-sense c.196C>T p.Gln66* rs1801770
c.3113G>A p.Trp1038* rs1801771
Frameshift c.1947_1948insA p.Glu650fs*13 -
c.2982_2983insT p.Ala995fs*16 rs1801771









*indicates a protein truncation event.
aNumber based on transcript sequence (NM_024675), +1 as A of ATG start codon.
bIncluding one sample that was genotyped by Taqman probe-based assay.
cAll four samples were genotyped by Taqman probe-based assay.
dIncluding duplicated sample.
eConfirmed by Sanger sequencing.
fPreviously screened by HRM only.
gUpon HRM curve re-analysis, the variant was apparent.
hUpon chromatogram re-analysis, the variant was apparent.
iInitially detected by HRM, not by Sanger sequencing.We accurately detected all 56 variant calls identified
through previous mutation screening by Sanger se-
quencing and/or HRM, and Taqman probe-based
genotyping. Heterozygous variants were observed in
37.23% (35/94) to 62.33% (513/823) of read-pairs
(median = 51.23%). No false positive calls were assigned.
All three pairs of duplicated samples yielded concordant
genotypes.
The 56 calls comprised instances of 11 distinct genetic
variants, including two non-sense variants (PALB2:
c.196C>T and PALB2:c.3113G>A), two frameshift variants
(PALB2:c.1947_1948insA and PALB2:c.2982_2983insT),
four missense variants (PALB2:c.1010T>C, PALB2:c.1
676A>G, PALB2:c.2014G>C and PALB2:c.2993G>A) and
three synonymous variants (PALB2:c.1572A>G, PALB2:
c.3300T>G and PALB2:c.3495G>A). Additional in-
formation regarding genotyping results is available in
Table 1.
Our screening by Hi-Plex also detected one PALB2:
c.1470C>T carrier that was identified by HRM but not
reported by prior Sanger sequencing, and one PALB2:
c.2590C>T carrier that was not reported by either method.
Upon re-analysis of the respective chromatograms andsequencing and HRM) or genotyping assays
er Number of carriers (detected
by all used methods)
Number of carriers










39 - 1 heterozygotee,g,h
36 7 heterozygotes 1 heterozygote,e,f,g
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samples (Additional file 4).
Discordant results were observed for two samples
screened by Hi-Plex and HRM methods. The PALB2:
c.2993G>A variant was detectable upon re-analysis of
the HRM curve, whereas the PALB2:c.1676A>G carrier
was not (Table 1). All four additionally identified variants
were confirmed by follow-up Sanger sequencing.
Here, we have validated that Hi-Plex is capable of
accurate, cost-effective and rapid high-throughput muta-
tion screening using a series of 95 specimens previously
characterized for PALB2 genotype.
By performing single-step, highly-multiplexed PCR li-
brary-building, we avoided multiple manipulations, and
waste of biological material and reagents associated with
alternative methods [8]. Results reported here demon-
strate that not only does Hi-Plex extensively reduce labour
associated with amplification protocol optimization and li-
brary preparation, it also allows accurate screening with-
out the need for normalisation of individual barcoded
libraries before pooling and sequencing.
Easy and rapid library preparation did not compromise
sequencing efficiency as shown by the 99.93% of amp-
licons represented at ≥10×. It did not impact on the
sensitivity and specificity of variant detection either. All
previously identified genetic variants were detected using
our method. Furthermore, no false positive variants were
called. Discordant calls as compared to previous screens
proved to be genuine variants following confirmatory
Sanger sequencing or detectable upon re-analysis of
chromatograms and/or HRM curves. As stated previously,
Hi-Plex’s experimental strategy includes a primer design
tool that allows generation of primers for amplicons of
a defined size, which should be shorter than the length
of a sequencing read. As such, completely-overlapping
reads can be achieved when performing paired-end
sequencing. This allows stringent filtering of sequen-
cing chemistry-induced artefacts by only considering
variants that appear in both reads of pairs. In turn, this
allows highly accurate variant detection.
The screen for genetic variations across 95 specimens
reported here was achieved in two days at a cost of ~
AU$20/specimen, accounting for all aspects of library-
building, MPS and analysis (including technician time).
The equivalent Sanger sequencing-based screen would
take approximately two weeks and confer a total cost
of ~ AU$400/specimen.
This report shows that our Hi-Plex approach performs
with a sensitivity and accuracy suitable for diagnostic
application, while being more time- and cost-effective
than Sanger sequencing, the current “gold standard”
screening method. The mechanisms underlying Hi-Plex
suggest that higher parallelization should be achievable
without extensive protocol adjustment. Future experimentswill involve increasing the level of multiplexing of Hi-Plex,
with the aim of achieving robust thousands-plex multi-
plexing. Cost-effective and rapid methods for screening
are highly desirable for mutation scanning, particularly
in clinical settings, where eligibility is partly dictated by
cost of testing. Lower screening costs could help facilitate
the shift from single-gene to gene-panel screening and
support a new approach to personalised clinical genetics
service delivery.
Conclusions
In the context of research and ‘gene association’ studies,
Hi-Plex enables large-scale sequencing in genetic epi-
demiological studies at relatively low cost, with more
flexibility than currently offered commercial solutions
where targeted sequencing is often constrained to specific
platforms. The latter confer design inflexibilities and are
costly to re-design in a setting where screening strategies
are often re-directed by recent findings. Hi-Plex’s intrinsic
modular flexibility in terms of target region design, as
well as sequencing platform, renders the approach highly
attractive for an extensive range of clinical and research
applications.
Additional files
Additional file 1: Hi-Plex primers used in this study. The data
provided correspond to the oligonucleotide sequences of all
gene-specific primers used in this study.
Additional file 2: Dual-indexed hybrid adapters and MiSeq primers
used in this study. The data provided correspond to the
oligonucleotide sequences of all adapters and sequencing primers used
in this study.
Additional file 3: BAM files visualized using the Integrated Genome
Viewer (IGV). Alignment and coverage tracks for five randomly selected
sample, following library preparation using Hi-Plex. The data provided
correspond to the IGV view from 5 randomly selected BAM files.
Additional file 4: Chromatograms from PALB2:c.2014G>C and
PALB2:c.2590C>T carriers (initial Sanger sequencing screening).
Hi-Plex identified one PALB2:c.2014G>C and one PALB2:c.2590C>T variant
carriers, which were not reported in the previous Sanger sequencing screen.
Both variants were detectable upon re-analysis of the initial chromatograms
(A and B, respectively). The variant positions are indicated by an arrow.
Genotypes are indicated on the figure.
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